LTV1

Across TCGA pan-cancer cohorts, LTV1 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated LTV1 data layer compared with 25 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher LTV1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated LTV1 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, PDAC, and LSCC are the cancer types where LTV1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	1.000	0.879	.001	71	view →
PDAC	DFS	Median	II,III,IV	0.880	0.672	.001	25	view →
LSCC	DFS	Quartile	II,III,IV	0.944	0.558	.006	21	view →
CCRCC	DFS	Quartile	III,IV	0.751	1.000	.008	13	view →
COAD	DFS	Median	All	1.000	0.888	.023	12	view →
GBM	OS	Median	All	0.652	0.385	.020	9	view →
HNSC	OS	Median	III,IV	1.000	0.484	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

LTV1–LUAD (OS)

Open the LUAD breakdown →